Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy

Purpose Younger age and female sex have already been well-known risk factors for chemotherapy-induced nausea and vomiting (CINV), and 30–50% of cancer patients still suffer from CINV. Genetic polymorphisms are suggested to influence antiemetic treatment response. Methods This study included a subset...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2018-05, Vol.26 (5), p.1505-1513
Main Authors: Yokoi, Mari, Tsuji, Daiki, Suzuki, Kenichi, Kawasaki, Yohei, Nakao, Masahiko, Ayuhara, Hideaki, Kogure, Yuuki, Shibata, Kazuhiko, Hayashi, Toshinobu, Hirai, Keita, Inoue, Kazuyuki, Hama, Toshihiro, Takeda, Koji, Nishio, Makoto, Itoh, Kunihiko
Format: Article
Language:English
Subjects:
Antineoplastic agents
Cancer
Chemotherapy
Gastrointestinal agents
Genetic aspects
Genetic polymorphisms
Genetic research
Genetics
Health risk assessment
Medical research
Medicine
Medicine & Public Health
Nausea
Nursing
Nursing Research
Oncology
Original Article
Pain Medicine
Patient compliance
Pharmacogenomics
Regression analysis
Rehabilitation Medicine
Risk factors
Side effects
Vomiting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Younger age and female sex have already been well-known risk factors for chemotherapy-induced nausea and vomiting (CINV), and 30–50% of cancer patients still suffer from CINV. Genetic polymorphisms are suggested to influence antiemetic treatment response. Methods This study included a subset of patients previously enrolled in a randomised controlled trial; 156 patients were evaluated. This study aimed to evaluate the role of pharmacogenomic polymorphisms relevant to antiemetic response in patients with cancer receiving cisplatin-based chemotherapy. The study’s efficacy endpoint was the proportion of patients with complete response (CR). The study endpoint was evaluated separately in the acute (CR 0–24 ) and delayed (CR 24–120 ) phases. Thirteen polymorphisms were genotyped, and the association of these genotypes with the efficacy of prophylactic antiemetics was then investigated. Confounding variables for the CR were identified using stepwise multivariate logistic regression analysis. Age and sex were included as independent variables by the forced-entry method, and the stepwise method was used to select the pharmacogenomic factors for inclusion as independent variables. Results Multivariate logistic regression analysis revealed that the ERCC1 8092AA (odds ratio [OR] = 11.25; 95% confidence interval [CI] 1.74–72.71; p  = 0.011) and female sex (OR = 3.63; 95% CI 1.14–11.58; p  = 0.029) were significant predictors of CR 0–24 . No significant association of CR 24–120 with pharmacogenomic polymorphisms was found via multivariate logistic regression analysis. Conclusions ERCC1 polymorphism influenced the extent of CINV control in patients receiving cisplatin-based chemotherapy. Trial registration Clinical trial information: UMIN 000009335
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-017-3974-3